Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

Orsini, Diego; Caldarola, Giacomo; Dattola, Annunziata; Campione, Elena; Bernardini, Nicoletta; Frascione, Pasquale; De Simone, Clara; Richetta, Antonio G.; Galluzzo, Marco; Skroza, Nevena; Assorgi, Chiara; Amore, Emanuele; Falco, Gennaro M.; Gaeta Shumak, Ruslana; Artosi, Fabio; Maretti, Giulia; Potenza, Concetta; Bianchi, Luca; Pellacani, Giovanni; Peris, Ketty; Bonifati, Claudio; Graceffa, Dario

doi:10.1080/09546634.2024.2319304

Cited by 4 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…58 Finally, real-life experiences confirmed the effectiveness of this drug. [59][60][61][62][63][64][65][66][67]…”

Section: Tildrakizumabmentioning

confidence: 99%

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Potestio,

Martora,

Lauletta

et al. 2024

CCID

View full text Add to dashboard Cite

Psoriasis pathogenesis is influenced by genetic factors and characterized by a complex interplay between genetic predisposition and various environmental triggers. These triggers set off metabolic processes involving inflammation, cell signaling, immune response dysregulation, and antigen presentation. Several types of innate and adaptive immune cells are involved in psoriasis. Among the cytokine cascade which leads to psoriasis development, the interleukin (IL)-23/Th17 axis, especially IL-17 production, emerges as crucial. Recognizing the pivotal role of this axis has facilitated the development of selective and effective biological drugs, such as anti-IL17 and anti-IL23 monoclonal antibodies. These drugs aim to achieve the complete or near-complete disappearance of psoriatic lesions, as indicated by PASI100 and PASI90 responses, respectively. In this context, the aim of our review was to delve into the functioning of the IL-23/Th17 axis, its dysregulation in psoriasis pathogenesis, and the therapeutic potential of its inhibition. Currently, 4 anti-IL17 (secukinumab, ixekizumab, bimekizumab and brodalumab) and 3 anti-IL23 (guselkumab, risankizumab and tildrakizumab) have been approved. All these drugs showed high levels of effectiveness in both clinical trials and real-life experiences, with an excellent profile in terms of safety. Certainly, furthers studies will allow for better characterization of biologics’ profile, in order to administer the right drug for the right patients at the right moment.

show abstract

“…58 Finally, real-life experiences confirmed the effectiveness of this drug. [59][60][61][62][63][64][65][66][67]…”

Section: Tildrakizumabmentioning

confidence: 99%

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Potestio,

Martora,

Lauletta

et al. 2024

CCID

View full text Add to dashboard Cite

show abstract

Effectiveness of tildrakizumab 200 mg: an Italian multicenter study

Dattola,

Bernardini,

Svara

et al. 2024

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience

Cacciapuoti,

Potestio,

Gallo

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundNovel biologics targeting the IL23/T‐17 axis, such as tildrakizumab, have been developed to treat psoriasis. There is limited evidence on the use of tildrakizumab for the treatment of psoriasis in difficult‐to‐treat areas.ObjectiveOur aim was to evaluate the short‐term efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis and with the involvement of difficult‐to‐treat areas.MethodsA multicentric retrospective study was conducted on patients who initiated tildrakizumab between July 2022 and July 2023. Psoriasis Area and Severity Index (PASI), Psoriasis Scalp Severity Index (PSSI), Palmoplantar Psoriasis Area and Severity Index (ppPASI), and Nail Psoriasis Severity Index (NAPSI) were measured at baseline and after 16 weeks. The percentages of achieving a PASI75, PASI90, or PASI100 response were assessed. Dermatology Life Quality Index (DLQI) and Itch Visual Analog Scale (VAS) were measured simultaneously. Data about potential safety issues and adverse events were collected.ResultsA total of 76 patients were included, and 59 (77.6%) were affected by psoriasis localized to the scalp (n = 32), palmoplantar locations (n = 13), or nails (n = 14). The mean PASI score decreased from 16.5 ± 9.8 at baseline to 1.9 ± 1.6 after 16 weeks. Tildrakizumab treatment resulted in the improvement of PSSI (19.9 ± 10.7 to 2.7 ± 4.2), ppPASI (15.4 ± 6.9 to 1.9 ± 2.3), and NAPSI (20.3 ± 16.9 to 7.6 ± 10.8) from baseline to 16 weeks, respectively. DLQI and Itch VAS also showed marked improvement.ConclusionsTildrakizumab is a valuable option for treating difficult‐to‐treat psoriasis and pruritus, with rapid onset of action.

show abstract

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

Cited by 4 publications

References 42 publications

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Effectiveness of tildrakizumab 200 mg: an Italian multicenter study

Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience

Contact Info

Product

Resources

About